Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

This is a randomized, double-blind, single dose, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of NCTX (PEGylated Liposomal Iodixanol Injection) administered intravenously to healthy volunteers. In addition, computed tomography (CT) scans will be acquired to measure radiographic density in regions of interest (ROI) at times from 3-5 hours and up to 72 hours following NCTX administration.

Key facts

Study ID

NCT02063594

Run by

Marval Pharma Ltd.

People needed

20

Starts

2014-03-01

Expected to finish

2014-10-01

Last updated by the study team

2014-10-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy, nonsmoking men and women 18 to 55 years of age
• Body Mass Index (BMI) between 18.5 and 30.0 kg/m2
• Serum creatinine within normal range and calculated creatinine clearance of 80 mL/min/1.73 m2 or greater

You may not qualify if…

• Concurrent enrollment in another clinical trial or treatment with any investigational products or therapies within 30 days prior to dosing
• History of infusion reactions to liposomes, nanoparticles, monoclonal antibodies, or intravenously administered materials
• History of allergic/anaphylactoid-like reactions attributed to iodinated contrast agents or other components of the formulation
• Disturbances in normal fat metabolism, or total cholesterol greater than 240 mg/dL
• Pregnant or nursing women
• Exposure to significant radiation within 1 year, or previous CT scan within 5 years prior to check-in

Where it is running

• Quintiles Phase 1 Services — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.